🔴 Neurosense Therapeutics is trading 6.6% down in pre-market on October 20, 2026 amid biotech weakness

Neurosense Therapeutics is trading at $2.49, down 6.57% in pre-market, with no verified company-specific catalyst identified.

• The October 19 U.S. patent application for PrimeC’s potential traumatic brain injury use was positive expansion news, not an identified explanation for the decline.
• Biotech ETF XBI was down 3.65% pre-market amid broader market concerns. Sector weakness may be contributing, but this does not establish a direct cause.